JP2023516286A5 - - Google Patents
Info
- Publication number
- JP2023516286A5 JP2023516286A5 JP2022550781A JP2022550781A JP2023516286A5 JP 2023516286 A5 JP2023516286 A5 JP 2023516286A5 JP 2022550781 A JP2022550781 A JP 2022550781A JP 2022550781 A JP2022550781 A JP 2022550781A JP 2023516286 A5 JP2023516286 A5 JP 2023516286A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- domain containing
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/076937 | 2020-02-27 | ||
| CN2020076937 | 2020-02-27 | ||
| PCT/CN2021/078203 WO2021170100A1 (en) | 2020-02-27 | 2021-02-26 | Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023516286A JP2023516286A (ja) | 2023-04-19 |
| JP2023516286A5 true JP2023516286A5 (enExample) | 2024-02-29 |
| JP7747645B2 JP7747645B2 (ja) | 2025-10-01 |
Family
ID=77490732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550781A Active JP7747645B2 (ja) | 2020-02-27 | 2021-02-26 | グリピカン－３（ｇｐｃ３）を標的化する抗体及びキメラ抗原受容体並びにその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230088461A1 (enExample) |
| EP (1) | EP4110912A4 (enExample) |
| JP (1) | JP7747645B2 (enExample) |
| KR (1) | KR20220146456A (enExample) |
| CN (1) | CN115151639A (enExample) |
| AU (1) | AU2021225978A1 (enExample) |
| BR (1) | BR112022016958A2 (enExample) |
| CA (1) | CA3170023A1 (enExample) |
| IL (1) | IL295774A (enExample) |
| MX (1) | MX2022010360A (enExample) |
| WO (1) | WO2021170100A1 (enExample) |
| ZA (1) | ZA202209069B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260116991A1 (en) * | 2021-02-03 | 2026-04-30 | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | Monoclonal antibody for specifically recognizing glypican-3, and application thereof |
| JP2024507958A (ja) * | 2021-02-26 | 2024-02-21 | ナンジン レジェンド バイオテック カンパニー，リミテッド | 外因的に導入されたサイトカインを発現する操作された免疫エフェクター細胞 |
| JP2025524921A (ja) * | 2022-07-29 | 2025-08-01 | レジェンド バイオテック アイルランド リミテッド | 細胞療法の持続性を促進するための方法 |
| EP4562046A1 (en) * | 2022-07-29 | 2025-06-04 | Legend Biotech Ireland Limited | Claudin-6 binding moieties and uses thereof |
| CN117025541B (zh) * | 2023-08-15 | 2025-10-17 | 福建医科大学附属协和医院 | 一种靶向b7-h3并共表达细胞因子和趋化因子的car-t细胞及其用途 |
| KR20250116580A (ko) * | 2024-01-24 | 2025-08-01 | 국립암센터 | Gpc3에 특이적으로 결합하는 신규 항체를 이용한 키메라 항원 수용체 t 세포 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050020806A (ko) * | 2002-05-23 | 2005-03-04 | 써니브룩 앤드 우먼스 칼리지 헬스 사이언시즈 센터 | 간세포암의 진단 |
| CN1894587A (zh) * | 2003-10-29 | 2007-01-10 | 财团法人熊本高新技术产业财团 | 恶性黑色素瘤(melanoma)的诊断试剂 |
| AU2005256113B2 (en) | 2004-07-09 | 2011-02-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
| US7723043B2 (en) * | 2006-01-04 | 2010-05-25 | Picobella, Lp | Methods for screening for prostate cancer |
| CN104520331B (zh) * | 2012-06-01 | 2018-09-07 | 美国政府(由卫生和人类服务部的部长所代表) | 磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途 |
| JP2017522861A (ja) | 2014-05-22 | 2017-08-17 | ジェネンテック， インコーポレイテッド | 抗ｇｐｃ３抗体及びイムノコンジュゲート |
| ES2851123T1 (es) * | 2014-09-26 | 2021-09-03 | Baylor College Medicine | Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva |
| US20160208018A1 (en) * | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| WO2018059549A1 (en) * | 2016-09-30 | 2018-04-05 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
| TWI831365B (zh) * | 2017-01-10 | 2024-02-01 | 國立大學法人山口大學 | 抗ｇｐｃ３抗體 |
| EP3615574B1 (en) | 2017-04-26 | 2026-06-24 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
| CN109385400A (zh) * | 2017-08-09 | 2019-02-26 | 科济生物医药（上海）有限公司 | 共表达pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| AR114112A1 (es) * | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
| WO2020017479A1 (ja) | 2018-07-17 | 2020-01-23 | ノイルイミューン・バイオテック株式会社 | 抗ｇｐｃ３一本鎖抗体を含むｃａｒ |
| CN110684120B (zh) * | 2019-10-12 | 2023-03-07 | 华夏源（上海）细胞基因工程股份有限公司 | 一种靶向gpc3的嵌合抗原受体及其应用 |
-
2021
- 2021-02-26 JP JP2022550781A patent/JP7747645B2/ja active Active
- 2021-02-26 MX MX2022010360A patent/MX2022010360A/es unknown
- 2021-02-26 AU AU2021225978A patent/AU2021225978A1/en active Pending
- 2021-02-26 US US17/798,541 patent/US20230088461A1/en active Pending
- 2021-02-26 CA CA3170023A patent/CA3170023A1/en active Pending
- 2021-02-26 IL IL295774A patent/IL295774A/en unknown
- 2021-02-26 CN CN202180016268.2A patent/CN115151639A/zh active Pending
- 2021-02-26 BR BR112022016958A patent/BR112022016958A2/pt unknown
- 2021-02-26 WO PCT/CN2021/078203 patent/WO2021170100A1/en not_active Ceased
- 2021-02-26 KR KR1020227028720A patent/KR20220146456A/ko active Pending
- 2021-02-26 EP EP21759551.1A patent/EP4110912A4/en active Pending
-
2022
- 2022-08-12 ZA ZA2022/09069A patent/ZA202209069B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102785140B1 (ko) | 신규 항-cd3엡실론 항체 | |
| JP2021094037A5 (enExample) | ||
| CA3016287A1 (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| RU2020120853A (ru) | Мультиспецифичные химерные рецепторы, содержащие домен nkg2d, и способы их применения | |
| CA3148329A1 (en) | Targeted immunotolerance with a pd-1 agonist | |
| KR20230143177A (ko) | 신규한 항-cd24 항체 | |
| JP2022542559A5 (enExample) | ||
| RU2019126655A (ru) | Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль | |
| RS53072B (sr) | Antitela za humani receptor programirane smrti pd-1 | |
| KR20230024911A (ko) | 항-her2 항체 또는 이의 항원 결합 단편 및 이를 포함하는 키메라 항원 수용체 | |
| CN115279792B (zh) | 对bcma特异的抗体及嵌合抗原受体 | |
| CA3072394A1 (en) | Cd96-binding agents as immunomodulators | |
| CA3219642A1 (en) | Novel anti-cd276 antibodies and the uses thereof | |
| EP3873936A1 (en) | Novel antagonistic anti tnfr2 antibody molecules | |
| JP2025504795A (ja) | 抗体及びその用途 | |
| JP2024105603A (ja) | ＣＡＲライブラリおよびｓｃＦｖの製造方法 | |
| CA3199976A1 (en) | Polypeptide constructs selectively binding to cldn6 and cd3 | |
| WO2025148750A1 (zh) | 膜表达il-10及其用途 | |
| US20260055201A1 (en) | Bispecific antibody and use thereof | |
| AU2023411874A1 (en) | Antibody and use thereof | |
| AU2023365438A1 (en) | Use of anti-cldn4-anti-cd137 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment | |
| KR20240002205A (ko) | 면역관문 제어 인자를 발현하는 면역세포 및 이의 용도 | |
| CN115991786A (zh) | 用于靶向msln免疫细胞疗法的组合物 | |
| EA052500B1 (ru) | Новые антитела против cd24 |